Truist Financial’s Amneal Pharmaceuticals AMRX Stock Holding History

Truist Financial’s Portfolio AMRX Stock Details AMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$765K	Buy	44,222 +7,987	+22%	+$109K	﹤0.01%	1931
2026 Q1	$450K	Buy	36,235 +10,627	+41%	+$143K	﹤0.01%	2133
2025 Q4	$323K	Buy	25,608 +11,944	+87%	+$137K	﹤0.01%	2283
2025 Q3	$137K	Buy	+13,664	New	+$123K	﹤0.01%	2605
2024 Q2	–	Sell	-65,130	Closed	-$395K	–	2644
2024 Q1	$395K	Hold	65,130	–	–	﹤0.01%	2130
2023 Q4	$395K	Buy	+65,130	New	+$290K	﹤0.01%	2131
2022 Q4	–	Sell	-24,896	Closed	-$50K	–	2559
2022 Q3	$50K	Sell	24,896 -35,948	-59%	-$101K	﹤0.01%	2468
2022 Q2	$193K	Hold	60,844	–	–	﹤0.01%	2454
2022 Q1	$254K	Hold	60,844	–	–	﹤0.01%	2413
2021 Q4	$291K	Hold	60,844	–	–	﹤0.01%	2384
2021 Q3	$325K	Sell	60,844 -14,541	-19%	-$73.2K	﹤0.01%	2288
2021 Q2	$386K	Buy	+75,385	New	+$428K	﹤0.01%	2225
2020 Q4	–	Sell	-10,000	Closed	-$39K	–	2543
2020 Q3	$39K	Hold	10,000	–	–	﹤0.01%	2400
2020 Q2	$48K	Hold	10,000	–	–	﹤0.01%	2337
2020 Q1	$35K	Sell	10,000 -83	-0.8%	-$352	﹤0.01%	2316
2019 Q4	$49K	Buy	+10,083	New	+$35K	﹤0.01%	2443

Other funds holding AMRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Truist Financial's AMRX Position: Q2 2026 in Review

Truist Financial increased its Amneal Pharmaceuticals (AMRX) stake by 22% in Q2 2026, buying an estimated $109K and bringing the position to 44,222 shares worth $765K. The position accounts for ﹤0.01% of the portfolio, ranked #1931.

Truist Financial first reported a position in AMRX in Q4 2019 and has held it in 16 quarters since. 310 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.

Truist Financial held 44,222 shares of Amneal Pharmaceuticals worth $765K as of Q2 2026.
Truist Financial bought 7,987 Amneal Pharmaceuticals shares in Q2 2026, an estimated $109K.
Amneal Pharmaceuticals made up ﹤0.01% of Truist Financial's portfolio in Q2 2026, its #1931 holding.
Truist Financial first reported a position in Amneal Pharmaceuticals in Q4 2019 and has held it in 16 quarters since.
310 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.

Based on Truist Financial's 13F filing for Q2 2026, filed 28 Jul 2026.